As should be clear from our content on this portal, 20/20 went all in on its pandemic response more than 12 months ago. In March of 2020 we became one of the first companies to clinically validate and make available rapid antibody tests at a time when there were few viable testing alternatives in the U.S. Later in the year we installed PCR testing equipment in our lab and have now become one of the leading providers of Covid-19 testing for the Montgomery County Maryland Health Department. Notably Montgomery County is home to the FDA, NIH, and one of the largest life science communities in the country.
What all this means for our long term prospects should be front of mind among those considering an investment in 20/20. For that we recommend an excellent opinion piece that appeared last week in Barrons by Rahul Dhanda. See Beyond Covid, the Future of Healthcare Looks Bright for Investors
This combination of diagnostic tests and vaccines—especially the revolutionary mRNA technologies developed by Moderna and Pfizer/BioNTech—won’t merely end the pandemic. It will revolutionize healthcare and save millions of lives for decades to come...But to realize that potential, the medical community will need to overhaul its approach to diagnostic testing.
Before the pandemic, many doctors considered diagnostics an unnecessary luxury. Just last year, a study in the Open Forum Infectious Diseases journal found that rapid diagnostic tests were used infrequently in outpatient settings at urban safety-net hospitals. An earlier analysis in JAMA Pediatrics found that adolescent Medicaid hypertension patients rarely receive the recommended diagnostic tests.
Even the most elite healthcare providers underuse diagnostic tests. One recent study by researchers at Johns Hopkins University suggests that particularly accomplished physicians may undertest patients as a way of signaling their expertise to fellow practitioners.
Instead of relying on diagnostic tests, many providers play Dr. House. They attempt to diagnose diseases through a trial-and-error process, trying multiple interventions before arriving at an effective treatment, or even an accurate diagnosis...Normalizing the use of diagnostic testing would allow doctors to detect illnesses earlier and treat them more successfully. Consider screenings for cancer, one of the only diseases where diagnostic testing is relatively common. It’s the exception that proves the rule. Widespread use of mammograms probably prevented at least 27,000 breast cancer deaths in 2018 alone. Imagine if we routinely tested for other infectious diseases with the same urgency as we have for Covid-19. We must continue to invest in and expand diagnostic solutions post pandemic.
Investors would do well to pay attention to advances in this field and stick with the companies making them over the long haul. For the first time, molecular diagnostics is simple enough to be self-administered, allowing point-of-care testing at medical centers—and even in patients’ homes—and creating a $4 billion market for at-home Covid-19 testing almost overnight. An increase in chromosomal abnormalities like Down syndrome is driving the global market for noninvasive prenatal testing. Liquid biopsies, or blood tests that detect several types of early-stage cancer, could soon be a $130 billion market opportunity in the U.S. alone. (Emphasis ours)
We fundamentally agree with this assessment and believe that 20/20 GeneSystems will continue to be a leader in the application of machine learning powered by real-world data to substantially disrupt laboratory medicine. We encourage you to invest here if you have not done so already. Thank you for your continued support!
Note: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.